This toner removes impurities, balances pH, and enhances your skins natural tone
Series A, Biological Sciences and Medical Sciences 78 (1): 7589
Russia: Approved prescription medication since 2009 Marketed as Selanc nasal spray (0.15% solution) Indicated for generalized anxiety disorder and neurasthenic conditions Available through pharmacies with a physician's prescription United States: Not FDA-approved for any indication Not classified as a controlled substance (not DEA-scheduled) In September 2024, Selank acetate (TP-7) was removed from the FDA's Category 2 bulk drug substances list because the nominators withdrew their nominations, not because the FDA cleared it for safety Status for compounding use under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act remains under review pending Pharmacy Compounding Advisory Committee evaluation Cannot legally be marketed as a drug, food, or dietary supplement with therapeutic claims Available as a research chemical from unregulated suppliers European Union, United Kingdom, Canada, Australia: Not approved by the EMA, MHRA, Health Canada, or TGA Exists in a regulatory gray area as a research compound Importation for personal use varies by jurisdiction and is subject to customs enforcement The regulatory asymmetry between Russia (where Selank is an established pharmaceutical) and Western countries (where it remains unapproved) reflects differences in clinical trial standards and regulatory pathways rather than any specific safety finding that has prevented approval
Concerning lipedema, all patients were at stage 3
